SEC Comment Letter 0000000000-23-000707 to Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786) (HOTH)
Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786)
Date: Jan. 23, 2023 · CIK: 0001711786 · Accession: 0000000000-23-000707
AI Filing Summary & Sentiment
File numbers found in text: 333-269224
Letter
United States securities and exchange commission logo January 23, 2023 Robb Knie Chief Executive Officer Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 Re:Hoth Therapeutics, Inc. Registration Statement on Form S-3 Filed January 13, 2023 File No. 333-269224 Dear Robb Knie: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Arzhang Navai at 202-551-4676 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nazia J. Khan, Esq.
Show Raw Text
United States securities and exchange commission logo
January 23, 2023
Robb Knie
Chief Executive Officer
Hoth Therapeutics, Inc.
1 Rockefeller Plaza, Suite 1039
New York, New York 10020
Re:Hoth Therapeutics, Inc.
Registration Statement on Form S-3
Filed January 13, 2023
File No. 333-269224
Dear Robb Knie:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Arzhang Navai at 202-551-4676 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Nazia J. Khan, Esq.